Stockreport

Abeona Therapeutics: Early Zevaskyn Revenue Marks A Key Inflection Point [Seeking Alpha]

Abeona Therapeutics Inc.  (ABEO) 
Last abeona therapeutics inc. earnings: 3/16 04:20 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.abeonatherapeutics.com
PDF Zevaskyn, an autologous gene therapy priced at $3.1M per treatment, targets a small but high-value RDEB patient population, with initial product revenue of $2.4M from a [Read more]